A prospective phase II study of induction chemotherapy and nimotuzumab for resectable locally advanced head and neck squamous cell carcinoma.

Xiaoying Zhao(Handan College), Qinghai Ji(Fudan University Shanghai Cancer Center), Guopei Zhu(Fudan University Shanghai Cancer Center), Yu Wang(Guizhou University), Chaosu Hu(Ministry of Agriculture and Rural Affairs), Yongxue Zhu(Fudan University), Ye Guo(Army Medical University)
Journal of Clinical Oncology
May 20, 2012
10.1200/jco.2012.30.15_suppl.e16039
Cited by 3

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline
|Journal of Clinical Oncology|2021|393
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma
|Radiotherapy and Oncology|2017|374